RecruitingPhase 4NCT05550194

VZV in the Enteric Nervous System: Pathogenesis and Consequences


Sponsor

Vanderbilt University Medical Center

Enrollment

40 participants

Start Date

Mar 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Varicella zoster virus (VZV) is the cause of chickenpox and shingles, but it also infects, becomes latent, and reactivates in nerve cells of the bowel to cause a gastrointestinal disorder ("enteric shingles"). The Investigators recently found that a chronic active VZV infection, a form of enteric shingles, is associated with achalasia, a severe disease in which the passage of food from esophagus to stomach is impaired. We now propose to eradicate VZV to determine whether its association with achalasia is causal, to identify the genetic basis behind VZV reactivation in the esophagus, and the relationship of mast cells to enteric shingles and abdominal pain.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Shingrix and a drug called ValACYclovir 1000 MG for people with achalasia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGValACYclovir 1000 MG

Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).

BIOLOGICALShingrix

Vaccine indicated for prevention of herpes zoster


Locations(1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05550194


Related Trials